đź“Ł ADDS 2027 Save the Date!

We hope you'll consider joining us for our 5th meeting, ADDS 2027, taking place Feb 8-10, 2027 at the Georgian Terrace Hotel in Atlanta, GA.

NOTE: Our office will be closed Friday, June 19th in observance of Juneteenth. We will reopen at regular business hours on Monday, June 22nd.

Subscribe to Receive Updates

Case Study

Objective, Real-World Sleep Measures Strengthen Clinical Insights in Insomnia Trial

Sleep-gfx@2x

Overview

Chronic insomnia disorder, marked by ongoing difficulty falling or staying asleep, can have a profound impact on health, daily functioning, and overall quality of life. While cognitive behavioral therapy remains the gold-standard treatment, many patients with chronic insomnia rely on pharmacological options when access is limited or symptoms persist. 

Zelira Therapeutics conducted a randomized controlled trial to evaluate the effectiveness of a cannabinoid-based therapy (ZTL-101) for chronic insomnia. This study highlights how combining patient-reported and objective, real-world digital measures can deliver a more complete picture of treatment impact.

What You'll Learn

  • The evolving landscape of obesity management
  • Opportunities for future obesity treatments beyond weight loss
  • Payer challenges in GLP-1 drug pricing
  • The role of wearables in monitoring functional outcomes in obesity clinical trials

Get the Complimentary Case Study Now